Trastuzumab deruxtecan is changing the treatment paradigm of both HER2-positive (47, 48) and HER2-low (48) disease and sacituzumab govitecan are improving triple negative and HR-positive BC survival (49). Here, ERBB2 is linked to breast cancer.